Earnings Ahead

MBRX - Moleculin Biotech

1.41 0.09 6.82

Moleculin Biotech

Moleculin Biotech

About

Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers.


Headquarters

Houston, Texas, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

MBRX

Recent Earnings

Moleculin Biotech GAAP EPS of -$0.30



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Moleculin Biotech GAAP EPS of -$0.30
  • Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
  • Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
  • Moleculin Biotech GAAP EPS of -$0.24
  • Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
  • Moleculin begins human trial of WP1122 to treat COVID-19
  • Moleculin Biotech GAAP EPS of -$0.24 misses by $0.01
  • Moleculin cleared to conduct phase 1 study of WP1066 for treatment of recurrent brain tumor
  • Moleculin Biotech GAAP EPS of -$0.59 beats by $0.12
  • Moleculin gains 5% on FDA green light for Phase 1 study of WP1122 in glioblastoma multiforme
  • Moleculin Biotech EPS beats by $0.05
  • MHRA OKs phase 1 trial of Moleculin Biotech's COVID-19 treatment
  • Moleculin says no dose-limiting toxicity in early-stage study for lung cancer therapy
  • Moleculin Biotech EPS beats by $0.05
  • Moleculin gets approval to amend protocol in early-stage annamycin leukemia study
  • Moleculin starts enrollment in phase 1b/2 annamycin sarcoma lung metastases study
  • Moleculin Biotech to join Russell 2000 Index
  • Moleculin kicks off phase 1b/2 annamycin cancer trial
  • Moleculin Biotech EPS beats by $0.03
  • WPD pharmaceuticals to get $6.7M grant for development of Leukemia treatment
PEERS
Recent Earnings

Moleculin Biotech GAAP EPS of -$0.30

Earnings History

Date EPS / Forecast Revenue / Forecast
August 16, 2021 - / -0.1867 - / -90 Beat!
May 12, 2021 -0.2 / -0.23 -100 / -
April 5, 2021 - / -0.5667 - / -
March 24, 2021 -0.24 / -0.5767 - / -
November 13, 2020 -0.36 / -0.0933 - / -
August 12, 2020 -0.17 / -0.09 - / -
May 19, 2020 -0.02 / -0.06 - / -
March 19, 2020 -0.06 / -0.11 - / -
November 12, 2019 -0.09 / -0.09 - / -
Date Price Open High Low Vol Change ER
Mar 23 1.610 1.590
1.610
1.550
66.00K 3.87%
Mar 22 1.550 1.550
1.589
1.494
85.27K 2.65%
Mar 21 1.510 1.490
1.520
1.461
23.44K 2.03%
Mar 18 1.480 1.410
1.512
1.400
112.82K 3.50%
Mar 17 1.430 1.380
1.440
1.380
75.83K 3.62%
 
Mar 16 1.380 1.300
1.440
1.300
229.56K 8.66%
Mar 15 1.270 1.250
1.320
1.220
70.45K 3.25%
Mar 14 1.230 1.310
1.330
1.230
85.63K -6.11%
Mar 11 1.310 1.320
1.340
1.280
51.00K -0.76%
Mar 10 1.320 1.260
1.340
1.260
76.86K -1.49%
Mar 9 1.340 1.260
1.340
1.260
87.17K 6.35%
Mar 8 1.260 1.261
1.310
1.230
279.55K -0.79%
Mar 7 1.270 1.320
1.360
1.250
197.62K -3.79%
Mar 4 1.320 1.360
1.380
1.320
45.18K -2.94%
Mar 3 1.360 1.380
1.400
1.360
65.09K -2.16%
Mar 2 1.390 1.410
1.420
1.380
41.33K 0.72%
Mar 1 1.380 1.390
1.450
1.370
79.95K -0.72%
Feb 28 1.390 1.380
1.410
1.360
95.49K -1.42%
Feb 25 1.410 1.370
1.410
1.330
62.59K 5.22%
Feb 24 1.340 1.310
1.350
1.275
179.60K -2.19%